Ann: Leadership Transition, page-34

First 34 Last

Share
Profile

Follow
AgentQ

241 Posts.

80

31/05/23

13:38

Post #: 68056757
Share

Originally posted by vintage: ↑
It's a shame that the discussion here gets sullied by the moronic comments of the likes of rolling. It is clear that he/she is being opportunistic by attempting to seed doubt amongst loose hands in order to profit.

This is a 'storm in a teacup' at worst. Ron is not 'leaving'. He is transitioning to a role that, apparently, is more appropriate to both the Company's and his personal circumstances. Thus he is working at the management level for at least another year and at Board level for perhaps many years to come.

Much of Ron's work has been done. He has set up a brilliant team, overseen partnership building with Keysight, Nvidia, ASA, leading clinical advisors, 3 leading hospitals and perhaps a range of others such as GE Health and Phillip's, enormous success with the winning of non-dilutionary grants and getting the all important pivotal trials off the ground.

I would think that he feels that the team he has built up and mentored is more than capable of carrying on everything he has done and could do in the future. He is one of 30+ staff now, not one of 3 or 4 when he started. The mantle is now over to them.

I feel totally confident that Ron will continue - as board member and consultant - to contribute massively to the Company's future strategies. The more day to day roles that he is pulling back from will be more than capably covered by Scott, our largest shareholder.

If Ron was leaving suddenly and totally and selling all his shares, it would be a very different story. But that is FAR from the case, despite what some of the obfuscating manipulators here are, unsuccessfully, trying to say.
Expand
Well said Vintage.

Let's also not forget, Scott is arguably a very handsome guy.
Who Shares Held Options Held As at date
1 Scott Kirkland and entities 4,269,155 500,000 1/12/2022
2 Ron Weinberger and spouse 2,308,727 500,000 5/05/2023
3 John Keep and entities 2,054,670 300,000 1/12/2022

https://www.businessnewsaustralia.com/articles/emvision-founder-appointed-ceo-as-portable-brain-scanner-company-enters-stage-2-clinical-trial.html

EMV Price at posting: $1.40 Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

CHN

Chalice jumps on Putin nickel export ban threat – but then there's bad news

SS1

Sun Silver confirms high-grade extension theory at Maverick Springs with 79.6 g/t intercept

NEC

Nine Entertainment announces its CEO is stepping down – on an ex-divvy day

BRX

Belararox to grow copper footprint in Botswana with 4,286 square km tenure

3 stocks with antimony news on Thursday

CU6

Clarity progresses SECuRE trial with positive safety results

ASX Market Open: Local bourse to trade green | Thursday September 12

DXB

Dimerix begins recruiting young kidney disease patients in Mexico for Phase 3

GTR

GTI extends uranium mineralisation at Lo Hema through development drilling

MTM

Forget gallium: MTM says it's extracted gold from e-waste

	Who	Shares Held	Options Held	As at date
1	Scott Kirkland and entities	4,269,155	500,000	1/12/2022
2	Ron Weinberger and spouse	2,308,727	500,000	5/05/2023
3	John Keep and entities	2,054,670	300,000	1/12/2022